Radiopharm Theranostics Limited (RADX)
NASDAQ: RADX · Real-Time Price · USD
4.940
-0.050 (-1.00%)
At close: Mar 9, 2026, 4:00 PM EDT
5.10
+0.16 (3.24%)
After-hours: Mar 9, 2026, 4:17 PM EDT
Radiopharm Theranostics Ratios and Metrics
Market cap in millions USD. Fiscal year is July - June.
Millions USD. Fiscal year is Jul - Jun.
| Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Mar '26 Mar 9, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
| Market Capitalization | 57 | 34 | 12 | 24 | 26 | - |
| Market Cap Growth | 60.90% | 192.24% | -50.78% | -10.18% | - | - |
| Enterprise Value | 32 | 9 | 10 | 8 | 4 | - |
| Last Close Price | 4.99 | 4.64 | - | - | - | - |
| PS Ratio | 5.29 | 4.16 | 8.93 | 5.74 | - | - |
| PB Ratio | 1.73 | 1.21 | 0.64 | 0.78 | 0.61 | - |
| P/TBV Ratio | 12.86 | - | - | - | 5.56 | - |
| EV/Sales Ratio | 2.93 | 1.15 | 8.02 | 2.04 | - | - |
| Debt / Equity Ratio | - | - | - | - | - | -0.47 |
| Net Debt / Equity Ratio | -0.69 | -0.68 | -0.68 | -0.26 | -0.43 | -0.26 |
| Net Debt / EBITDA Ratio | 0.88 | 0.90 | 0.58 | 0.46 | 1.59 | - |
| Net Debt / FCF Ratio | 0.93 | 0.80 | 0.81 | 0.50 | 2.72 | -0.40 |
| Asset Turnover | 0.18 | 0.16 | 0.03 | 0.08 | - | - |
| Quick Ratio | 3.00 | 2.65 | 1.11 | 1.22 | 3.43 | 0.21 |
| Current Ratio | 3.01 | 2.67 | 1.30 | 1.23 | 3.46 | 0.21 |
| Return on Equity (ROE) | -92.10% | -109.20% | -131.49% | -63.78% | -96.82% | - |
| Return on Assets (ROA) | -28.33% | -27.70% | -30.04% | -22.57% | -29.86% | - |
| Return on Capital Employed (ROCE) | -54.80% | -49.10% | -64.90% | -46.30% | -26.40% | 932.90% |
| Earnings Yield | -54.07% | -73.69% | -274.09% | -97.15% | -79.40% | - |
| FCF Yield | -45.47% | -70.43% | -131.34% | -65.25% | -25.86% | - |
| Buyback Yield / Dilution | -114.63% | -438.49% | -26.36% | -68.74% | - | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.